semaglutide reduced the risk of the combined endpoint of CV death or HF events (103 [5·4%] of 1914 semaglutide vs 138 [7·5%] of 1829 placebo HR 0·69 [95% CI 0·53–0·89] p=0·0045 A pooled analysis of SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM thelancet.com/journals/lance…